✦ LIBER ✦

Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study

✍ Scribed by Bendell, Johanna C.; Tournigand, Christophe; Swieboda-Sadlej, Anna; Barone, Carlo; Wainberg, Zev A.; Kim, Jong Gwang; Pericay, Carles; Pastorelli, Davide; Tarazi, Jamal; Rosbrook, Brad; Bloom, Joanna; Ricart, Alejandro D.; Kim, Sinil; Sobrero, Alberto F.

Book ID: 122310609
Publisher: CIG Media Group, LP.
Year: 2013
Tongue: English
Weight: 292 KB
Volume: 12
Category: Article
ISSN: 1533-0028
DOI: 10.1016/j.clcc.2013.09.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Axitinib and/or bevacizumab with modifie

Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study

✍ Infante, Jeffrey R.; Reid, Tony R.; Cohn, Allen L.; Edenfield, William J.; Cesco 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 330 KB

3060 POSTER Final data from a large phas

3060 POSTER Final data from a large phase II trial of first-line bevacizumab plus classic or modified FOLFIRI in metastatic colorectal cancer (CRC)

✍ A. Sobrero; S. Ackland; S. Clarke; R. Perez-Carrión; S. Chiara; J. Gapski; P. Ma 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Bevacizumab plus FOLFIRI or FOLFOX as th

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis

✍ Byung Woog Kang; Tae Won Kim; Jae-Lyun Lee; Min-Hee Ryu; Heung Moon Chang; Chang 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 188 KB

A randomized, phase II, three-arm study

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer

✍ Rugo, Hope S.; Campone, Mario; Amadori, Dino; Aldrighetti, Daniela; Conte, PierF 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 333 KB

A multicenter phase II study of the stop

A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer

✍ Natsuko T. Okita, Taito Esaki, Eishi Baba, Daisuke Sakai, Shinya Tokunaga, Hiroy 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 174 KB

Commentary on a Phase III Trial of Bevac

Commentary on a Phase III Trial of Bevacizumab plus XELOX or FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer: The NO16966 Trial

✍ Preeta Tyagi; Axel Grothey 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 141 KB